COVID-19 vaccines in India: Expected Date & current status
Whole world is currently working on a cure of corona virus as many of the vaccines have reached the 2nd and 3rd stage of trails. So, now everyone is expecting to get rid of this pandemic sometime real soon in the upcoming months.
With 2nd largest populated territory of humans, India is also looking forward to start manufacturing the vaccine as soon as it gets approved.
UPDATED on 9th September 2020
Current status of COVID-19 vaccine in India
Right now, there are mainly 3 COVID-19 vaccine candidates that are undergoing trials in India.
- “ChAdOx1 nCoV-19/MenACWY vaccine” by – OXFORD & AstraZeneca (Serum institute, pune as manufacturing partner)
- “Covaxin” by – Bharat Biotech & ICMR
- “Zycov-D” by – Zydus Cadila
1. “ChAdOx1 nCoV-19/MenACWY vaccine”
by – OXFORD & AstraZeneca
Oxford university researchers have done the research work for this vaccine. Further, for the development & manufacturing, collaboration stays with British pharmaceutical giant – “AstraZeneca”
This vaccine has successfully completed initial trials as of mid-august & just entered into phase-3. 1600 people are already identified in 17 different COVID-19 centers all over the country for phase-3 trials.
So, as soon as this vaccine completes phase-3 trial & gets an approval from the concerned officials, it can be mass produced for community vaccination.
By the end of this year this vaccine is expected to get available for the use of common people. It may require two dosages.
Latest update on AstraZeneca vaccine (9th September 2020)
In the US, the company began enrolling 30,000 volunteers across dozens of sites on August 31.
But, Pharmaceutical company AstraZeneca said Tuesday it had “voluntarily paused” a randomized clinical trial of its coronavirus vaccine in what it called a routine action after a volunteer developed an unexplained illness.
They also added “This is a routine action which has to happen whenever there is a potentially unexplained illness in one of the trials, while it is investigated, ensuring we maintain the integrity of the trials.”
The vaccine, called AZD1222, uses a weakened version of a common cold causing adenovirus that has been engineered to code for the spike protein that the novel coronavirus uses to invade cells.
2. “Covaxin” by – Bharat Biotech & ICMR
It is an inactivated type of vaccine. This type of vaccine is composed of certain proteins or components of the virus to elicit an immune response. In order to stimulate a stronger immune response, an adjuvant such as alum is often added.
Clinical testing of his vaccine has completed and it is now approved for phase-1 & phase-2 trials.
In spite of regular claims by the BBL, it is expected to made available only in the mid of 2021.
3. “Zycov-D” by – Zydus Cadila
Now, about 1000 healthy adults have been already identified to perform phase-2 trials.
It is also expected to arrive at the same time as “CoVaxin”.
To know more on vaccine update, you must read this article,